Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Скринер
Новости
О нас

RGEN - Repligen Corporation Последние новости | Finranks

Home

/

RGEN

R

Repligen Corporation (RGEN)

NMS – Цена в реальном времени. Валюта: USD

113.60

-2.31 (-1.99%)

При закрытии: May 12, 2026, 4:00 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Repligen Corporation (RGEN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Repligen Corporation (RGEN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Repligen Corporation (RGEN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Repligen Corporation to Present at Bank of America Securities 2026 Global Healthcare Conference

Repligen Corporation to Present at Bank of America Securities 2026 Global Healthcare Conference

WALTHAM, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will participate in the Bank of America Securities 2026 Global Healthcare Conference, being held May 12-14 in Las Vegas, Nevada.

Repligen's Q1 Earnings & Revenues Beat Estimates, Stock Rises

Repligen's Q1 Earnings & Revenues Beat Estimates, Stock Rises

RGEN tops Q1 earnings and revenue estimates, sending shares higher as strong chromatography and analytics business aid growth. The company raises its 2026 EPS view.

Repligen Corporation (RGEN) Q1 2026 Earnings Call Transcript

Repligen Corporation (RGEN) Q1 2026 Earnings Call Transcript

Repligen Corporation (RGEN) Q1 2026 Earnings Call Transcript

Repligen (RGEN) Q1 Earnings and Revenues Beat Estimates

Repligen (RGEN) Q1 Earnings and Revenues Beat Estimates

Repligen (RGEN) came out with quarterly earnings of $0.48 per share, beating the Zacks Consensus Estimate of $0.38 per share. This compares to earnings of $0.39 per share a year ago.

Repligen Reports First Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance

Repligen Reports First Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance

WALTHAM, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter of 2026, covering the three-month period ended March 31, 2026. The Company is also providing updated financial guidance for the full year 2026.

Alger Mid Cap Growth Fund Q1 2026 Portfolio Review

Alger Mid Cap Growth Fund Q1 2026 Portfolio Review

Class A shares of the Alger Mid Cap Growth Fund underperformed the Russell Midcap Growth Index during the first quarter of 2026. FTAI Aviation Ltd., Vertiv Holdings Co. and Comfort Systems USA, Inc., were among the top contributors to performance. Repligen Corporation, AppLovin Corp., and Carvana Co. were among the top detractors from performance.

Видео

No Data

There is no data to display

Пресс-релизы

Repligen Reports First Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance

Repligen Reports First Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance

WALTHAM, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter of 2026, covering the three-month period ended March 31, 2026. The Company is also providing updated financial guidance for the full year 2026.

Repligen Opens European Training & Innovation Center in Breda, Expanding Global Customer Support Network

Repligen Opens European Training & Innovation Center in Breda, Expanding Global Customer Support Network

WALTHAM, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced the grand opening of its new Repligen Training & Innovation Center (“RTIC”) at its OPUS® Pre-packed Chromatography Columns manufacturing facility in Breda, the Netherlands. The RTIC buildout, which features product exhibits and purpose-built demonstration areas, was designed to provide customers with pre- and post-sales support, and a hands-on experience with Repligen's innovative bioprocessing solutions.

Repligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance

Repligen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance

WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter of 2025, covering the three- and twelve- month periods ended December 31, 2025. The Company is also providing financial guidance for the full year 2026.

Repligen Executive Chair Tony Hunt to Retire; Dr. Martin D. Madaus Elected Chair

Repligen Executive Chair Tony Hunt to Retire; Dr. Martin D. Madaus Elected Chair

WALTHAM, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that the Board has elected Dr. Martin D. Madaus as Chair of the Board, effective March 13, 2026. As previously communicated1, Tony Hunt is retiring from his role as Executive Chair and member of the Board of Directors effective this March 13th. Mr. Hunt will continue to serve as an advisor to Repligen through March 2027.